Action VTYX VENTYX BIOSCIENCES, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Ventyx Biosciences, Inc.

Actions

VTYX

US92332V1070

Temps réel estimé Cboe BZX
Autres places de cotation
 21:30:12 17/07/2024 		Varia. 5j. Varia. 1 janv.
3,005 USD -6,09 % Graphique intraday de Ventyx Biosciences, Inc. +22,95 % +21,46 %
11/06 Transcript : Ventyx Biosciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:40 AM
06/06 VENTYX BIOSCIENCES, INC. : Oppenheimer toujours positif ZM

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) added to Russell Small Cap Comp Value Index
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) added to Russell 3000 Value Index
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) added to Russell 3000E Index
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) added to Russell 2500 Value Index
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) added to Russell Microcap Index
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) dropped from Russell 2500 Growth Index
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) dropped from Russell Small Cap Comp Growth Index
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) dropped from Russell 3000 Growth Index
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) added to Russell 2000 Value Index
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) dropped from Russell 2000 Growth Index
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) added to Russell Microcap Value Index
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) added to Russell 3000E Value Index
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) dropped from Russell 3000E Growth Index
Ventyx Biosciences Preclinical Study of Obesity Control Candidate Shows Positive Results
Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers
Ventyx Biosciences, Inc. Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
Ventyx Biosciences Appoints Matthew Moore as Chief Operating Officer; Shares Rise
Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action VTYX
  4. Actualités Ventyx Biosciences, Inc.
  5. Autres langues